Acts ethically at the leadership level

☆ Follow

4 campaigns on this issue

As You Sow at S&P 500 companies ranked in the 100 Most Overpaid CEOs report, led by Warner Bros. Discovery
As You Sow · Warner Bros. Discovery, Amazon.com Inc., Apple Inc. · 2023 · The report says 21 S&P 500 companies saw at least 50 percent of their shares reject the chief executive's pay package in the year covered, a 25 percent increase on the 16 in the previous report, and that BlackRock voted against only 5.7 percent of S&P 500 pay packages in 2022 and Vanguard against only 4.8 percent.
Mercy Investment Services and United Church Funds at five drugmakers on drug pricing in executive pay, 2020
Mercy Investment Services · AbbVie, Amgen, Biogen · 2019 · Filed on 14 November 2019 for the 2020 proxy season at AbbVie, Amgen, Biogen, Eli Lilly and Pfizer, with Mercy Investment Services lead filer at Amgen and Eli Lilly and United Church Funds leading the engagement with AbbVie. It reached a vote at two of the five. AbbVie, 8 May 2020: not approved, 249,382,082 for, 773,211,511 against, 19,752,693 abstaining and 251,100,201 broker non-votes, or 24.4 percent of the votes cast for and against. Eli Lilly, 4 May 2020: not approved, 184,652,906 for, 570,094,648 against, 27,534,077 abstaining and 83,997,305 broker non-votes, or 24.5 percent. No proposal on drug pricing and executive pay appears in the certified results of Amgen's meeting on 19 May 2020, Biogen's on 3 June 2020 or Pfizer's on 23 April 2020.
United Church Funds and ICCR members at AbbVie on drug pricing risk in executive pay, 2018
United Church Funds · AbbVie · 2018 · Not approved at the 4 May 2018 annual meeting: 247,879,964 for, 887,590,325 against, 14,559,605 abstaining and 260,703,800 broker non-votes, which is 21.8 percent of the votes cast for and against. It was a first-time proposal, it survived AbbVie's attempt at the SEC to have it omitted from the proxy, and the proxy adviser ISS recommended a vote for it.
Michael Weinstein at Gilead Sciences on tying CEO pay to patient access, 2014
Michael Weinstein, an individual shareholder · Gilead Sciences · 2014 · Not approved at the 7 May 2014 annual meeting as Proposal 7: 26,726,195 for, 1,048,057,432 against, 157,155,528 abstaining and 115,351,928 broker non-votes, which is 2.5 percent of the votes cast for and against.

Organizations working on this

Amnesty International

Directs advocacy at investors rather than filing resolutions: it published letters to pension funds about their exposure to NSO Group spyware, and has called on venture capital firms to carry out human rights due diligence.

Bowyer Research

Is named as a participant in shareholder campaigns other investors led. It appears in campaigns at Netflix in 2025.

Free Enterprise Project (National Center for Public Policy Research)

Files shareholder resolutions in its own name. It has filed at 10 companies, among them The Walt Disney Company and Alphabet Inc. between 2019 and 2026.

Interfaith Center on Corporate Responsibility

The coalition at the center of faith-based shareholder advocacy in the United States for over fifty years, coordinating member institutions' engagements and resolutions.

Investors for Opioid Accountability

Files shareholder resolutions in its own name. It has filed at 6 companies, among them McKesson and and other opioid distributors and manufacturers in 2017.

Majority Action

Publishes proxy voting analysis that other investors vote on, and runs vote-no campaigns against named directors. It produces the Climate in the Boardroom report series (sixth edition covering the 2024 proxy season), an interactive Climate Proxy Voting Dashboard tracking the climate voting records of the 22 largest asset managers, stewardship checklists, and per-season vote guides, and it ran a Vote NO campaign at ExxonMobil and issued 2026 guidance recommending director no-votes at companies expanding gas-fired generation for data centers. Its own site does not describe it filing resolutions.